Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune Inc. shows a promising outlook due to its innovative pipeline targeting chronic inflammatory diseases, including EVO756 and EVO301, which are designed for conditions like chronic spontaneous urticaria and atopic dermatitis. The company's novel molecular structure has resulted in significant improvements in drug half-life and accessibility, enhancing the potential for success in additional IL-18-driven indications such as ulcerative colitis. Positive early clinical results, including a significant percentage of patients experiencing clinically meaningful improvements, position Evommune favorably for long-term growth and commercialization opportunities in these therapeutic areas.

Bears say

Evommune Inc faces a negative outlook primarily due to anticipated underperformance of its pipeline products EVO756 and EVO301 in a competitive market, which is expected to result in lower peak sales than previously estimated. Additionally, challenges in market uptake are likely to arise from heightened competition and obstacles to market access, contributing to slower than expected revenue growth. Furthermore, concerns regarding potential equity dilution due to financing needs could pose additional risks to the company's financial stability in the medium to long term.

Evommune Inc (EVMN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 7 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.